BIO

Olivia obtained her 3-year bachelor’s degree in Biomedicine at Lancaster University in 2020. She spent the second year of her degree studying at the University of Wollongong, Australia before returning to complete the final year. Olivia's final year project investigated the use of proteolysis-targeting chimeras (PROTACs) for targeted protein degradation as a therapeutic strategy in prostate cancer. She stayed on at Lancaster University to complete a MSc by Research degree in Biomedical Science. Olivia's research was focused on the evaluation of the cell cycle protein, Ciz1, as a biomarker and drug target in glioblastoma. In 2022, she began working for an industrial drug discovery company specialising in the application of high content screening in in vitro 3D liver models for early predictions of drug toxicity.

Olivia is currently a PhD student in the Nanomedicine lab at the University of Manchester. Her project within the nano-omics team is focused on the use of nanoparticles as scavenging agents for the longitudinal tracking of blood and brain proteomic signals, with the aim to uncover highly specific and reproducible blood biomarkers in glioblastoma.